SLC6A3 and drug-induced dyskinesia: However, in the context of dual DAT and SERT inhibition, further blockade of NET may result in too high striatal dopamine levels, the ultimate dopamine-buffering mechanism being neutralised, which might trigger or exacerbate dyskinesia.